Back to Search
Start Over
Topical Imiquimod in Primary Cutaneous Extramammary Paget's Disease: A Systematic Review.
Topical Imiquimod in Primary Cutaneous Extramammary Paget's Disease: A Systematic Review.
- Source :
-
Cancers [Cancers (Basel)] 2023 Nov 30; Vol. 15 (23). Date of Electronic Publication: 2023 Nov 30. - Publication Year :
- 2023
-
Abstract
- Extramammary Paget's disease (EMPD) is subclinical in extent and multifocal in nature. There is no global consensus for treatment, so its management represents a challenge in clinical practice. Therefore, we conducted a systematic review through the main electronic databases to assess the effectiveness of topical imiquimod in cutaneous EMPD and to discuss its management. Finally, 24 studies involving a total of 233 EMPD patients treated with topical imiquimod were selected. The topical imiquimod response rate was 67%, and the complete response (CR) rate was 48%. Patients were treated with a three-four times a week regimen in most cases, ranging between 2 to 52 weeks. In addition, imiquimod was applied as an adjunctive treatment in 21 patients, achieving a CR rate of 71%. Consequently, imiquimod therapy could achieve a good response ratio as a first-line treatment, as adjuvant and neo-adjuvant therapy, and as a treatment for recurrent disease. The heterogeneity between studies and the lack of a control arm made it impossible to conduct a meta-analysis. To improve the quality of evidence on EMPD, multicenter studies are essential to collect a larger number of patients and, consequently, obtain high-quality evidence to standardize treatment. The Prospero registration number is CRD42023447443.
Details
- Language :
- English
- ISSN :
- 2072-6694
- Volume :
- 15
- Issue :
- 23
- Database :
- MEDLINE
- Journal :
- Cancers
- Publication Type :
- Academic Journal
- Accession number :
- 38067369
- Full Text :
- https://doi.org/10.3390/cancers15235665